{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T18:16:34Z","timestamp":1783188994948,"version":"3.54.6"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,10,16]],"date-time":"2021-10-16T00:00:00Z","timestamp":1634342400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,16]],"date-time":"2021-10-16T00:00:00Z","timestamp":1634342400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:title>Abstract\n<\/jats:title><jats:p><jats:italic>Pseudomonas aeruginosa<\/jats:italic> isolates were consecutively collected from patients with pneumonia in 29 medical centers in 2020 and susceptibility tested by broth microdilution method. Ceftazidime-avibactam (95.5% susceptible), imipenem-relebactam (94.3% susceptible), and ceftolozane-tazobactam (93.3% susceptible) were the most active compounds after colistin (99.5% susceptible). Susceptibility rates for the \u03b2-lactam\/\u03b2-lactamase inhibitor combinations (BL\/BLIs) varied against isolates resistant to piperacillin-tazobactam, meropenem, imipenem, and\/or ceftazidime. Ceftazidime-avibactam was the most active BL\/BLI against resistant subsets from Western Europe, whereas imipenem-relebactam was slightly more active than other BL\/BLIs against resistant subsets from Eastern Europe. Susceptibility rates were markedly lower in Eastern Europe than Western Europe.<\/jats:p>","DOI":"10.1007\/s10096-021-04363-7","type":"journal-article","created":{"date-parts":[[2021,10,17]],"date-time":"2021-10-17T00:24:56Z","timestamp":1634430296000},"page":"319-324","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Comparative activity of newer \u03b2-lactam\/\u03b2-lactamase inhibitor combinations against Pseudomonas aeruginosa from patients hospitalized with pneumonia in European medical centers in 2020"],"prefix":"10.1007","volume":"41","author":[{"given":"Helio S.","family":"Sader","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia G.","family":"Carvalhaes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dee","family":"Shortridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Castanheira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,16]]},"reference":[{"issue":"3","key":"4363_CR1","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.ccc.2013.03.007","volume":"29","author":"GB Nair","year":"2013","unstructured":"Nair GB, Niederman MS (2013) Nosocomial pneumonia: lessons learned. Crit Care Clin 29(3):521\u2013546","journal-title":"Crit Care Clin"},{"issue":"5","key":"4363_CR2","doi-asserted-by":"publisher","first-page":"e61","DOI":"10.1093\/cid\/ciw353","volume":"63","author":"AC Kalil","year":"2016","unstructured":"Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, Napolitano LM, O\u2019Grady NP, Bartlett JG, Carratala J, El Solh AA, Ewig S, Fey PD, File TM Jr, Restrepo MI, Roberts JA, Waterer GW, Cruse P, Knight SL, Brozek JL (2016) Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis 63(5):e61\u2013e111","journal-title":"Clin Infect Dis"},{"issue":"11","key":"4363_CR3","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1007\/s10096-016-2703-z","volume":"36","author":"D Koulenti","year":"2017","unstructured":"Koulenti D, Tsigou E, Rello J (2017) Nosocomial pneumonia in 27 ICUs in Europe: perspectives from the EU-VAP\/CAP study. Eur J Clin Microbiol Infect Dis 36(11):1999\u20132006","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"4363_CR4","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlab117","author":"HS Sader","year":"2021","unstructured":"Sader HS, Streit JM, Carvalhaes CG, Huband MD, Shortridge D, Mendes RE, Castanheira M (2021) Frequency of occurrence and antimicrobial susceptibility of bacteria isolated from patients hospitalized with bacterial pneumonia in western Europe, eastern Europe, and the United States: Results from the SENTRY Program (2016\u20132019). JAC Antimicrob Resist. https:\/\/doi.org\/10.1093\/jacamr\/dlab117","journal-title":"JAC Antimicrob Resist"},{"key":"4363_CR5","doi-asserted-by":"publisher","first-page":"665759","DOI":"10.3389\/fcimb.2021.665759","volume":"11","author":"RF Langendonk","year":"2021","unstructured":"Langendonk RF, Neill DR, Fothergill JL (2021) The building blocks of antimicrobial resistance in Pseudomonas aeruginosa: implications for current resistance-breaking therapies. Front Cell Infect Microbiol 11:665759","journal-title":"Front Cell Infect Microbiol"},{"issue":"7","key":"4363_CR6","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1093\/cid\/ciab295","volume":"72","author":"PD Tamma","year":"2021","unstructured":"Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ (2021) Infectious Diseases Society of America guidance on the treatment of extended-spectrum beta-lactamase producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa). Clin Infect Dis 72(7):1109\u20131116","journal-title":"Clin Infect Dis"},{"issue":"4","key":"4363_CR7","doi-asserted-by":"publisher","first-page":"e00031","DOI":"10.1128\/CMR.00031-19","volume":"32","author":"JP Horcajada","year":"2019","unstructured":"Horcajada JP, Montero M, Oliver A, Sorl\u00ed L, Luque S, G\u00f3mez-Zorrilla S, Benito N, Grau S (2019) Epidemiology and treatment of multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa infections. Clin Microbiol Rev 32(4):e00031-e119","journal-title":"Clin Microbiol Rev"},{"key":"4363_CR8","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1186\/s13054-015-0926-5","volume":"19","author":"ST Micek","year":"2015","unstructured":"Micek ST, Wunderink RG, Kollef MH, Chen C, Rello J, Chastre J, Antonelli M, Welte T, Clair B, Ostermann H, Calbo E, Torres A, Menichetti F, Schramm GE, Menon V (2015) An international multicenter retrospective study of Pseudomonas aeruginosa nosocomial pneumonia: impact of multidrug resistance. Crit Care 19:219","journal-title":"Crit Care"},{"issue":"1","key":"4363_CR9","doi-asserted-by":"publisher","first-page":"e00115","DOI":"10.1128\/CMR.00115-20","volume":"34","author":"D Yahav","year":"2020","unstructured":"Yahav D, Giske CG, Gramatniece A, Abodakpi H, Tam VH, Leibovici L (2020) New beta-lactam-beta-lactamase inhibitor combinations. Clin Microbiol Rev 34(1):e00115","journal-title":"Clin Microbiol Rev"},{"issue":"6","key":"4363_CR10","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1093\/jac\/dkz074","volume":"74","author":"HS Sader","year":"2019","unstructured":"Sader HS, Castanheira M, Arends SJR, Goossens H, Flamm RK (2019) Geographical and temporal variation in the frequency and antimicrobial susceptibility of bacteria isolated from patients hospitalized with bacterial pneumonia: results from 20 years of the SENTRY Antimicrobial Surveillance Program (1997\u20132016). J Antimicrob Chemother 74(6):1595\u20131606","journal-title":"J Antimicrob Chemother"},{"key":"4363_CR11","unstructured":"CLSI (2018) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: eleventh edition M07. Clinical and Laboratory Standards Institute, Wayne, PA"},{"key":"4363_CR12","unstructured":"CLSI (2021) M100Ed31. Performance standards for antimicrobial susceptibility testing: 31st informational supplement. Clinical and Laboratory Standards Institute, Wayne, PA"},{"key":"4363_CR13","unstructured":"EUCAST (2021) Breakpoint tables for interpretation of MICs and zone diameters. Version 11.0, January 2021. European Committee on Antimicrobial Susceptibility Testing. Availabel at https:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Breakpoint_tables\/v_11.0_Breakpoint_Tables.pdf. Accessed Jul\u00a02021"},{"key":"4363_CR14","unstructured":"(2021) Recarbrio\u00ae (imipemen\/cilastatin\/relebactam).\u00a0https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/recarbrio-epar-product-information_en.pdf.\u00a0Accessed Jul 2021"},{"key":"4363_CR15","unstructured":"(2021) Vaborem\u00ae (meropenem-vaborbactam).\u00a0https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/vaborem-epar-product-information_en.pdf. Accessed Jul 2021"},{"key":"4363_CR16","unstructured":"(2021) Zavicefta\u00ae (ceftazidime-avibactam).\u00a0https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/zavicefta-epar-product-information_en.pdf. Accessed Jul 2021"},{"key":"4363_CR17","unstructured":"(2021) Zerbaxa\u00ae(ceftolozane-tazobactam). Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/zerbaxa-epar-product-information_en.pdf. Accessed Jul\u00a02021"},{"key":"4363_CR18","unstructured":"Antimicrobial resistance in the EU\/EEA (EARS-Net) - Annual Epidemiological Report for 2019. European Centre for Disease Prevention and Control. November 18 2020. https:\/\/www.ecdc.europa.eu\/en\/publications-data\/surveillance-antimicrobial-resistance-europe-2019#no-link"},{"issue":"1","key":"4363_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/ice.2019.296","volume":"41","author":"LM Weiner-Lastinger","year":"2020","unstructured":"Weiner-Lastinger LM, Abner S, Edwards JR, Kallen AJ, Karlsson M, Magill SS, Pollock D, See I, Soe MM, Walters MS, Dudeck MA (2020) Antimicrobial-resistant pathogens associated with adult healthcare-associated infections: summary of data reported to the National Healthcare Safety Network, 2015\u20132017. Infect Control Hosp Epidemiol 41(1):1\u201318","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"9","key":"4363_CR20","doi-asserted-by":"publisher","first-page":"2588","DOI":"10.1093\/jac\/dkz243","volume":"74","author":"M Castanheira","year":"2019","unstructured":"Castanheira M, Doyle TB, Smith CJ, Mendes RE, Sader HS (2019) Combination of MexAB-OprM overexpression and mutations in efflux regulators, PBPs and chaperone proteins is responsible for ceftazidime\/avibactam resistance in Pseudomonas aeruginosa clinical isolates from US hospitals. J Antimicrob Chemother 74(9):2588\u20132595","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"4363_CR21","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1093\/jac\/dkx424","volume":"73","author":"PA Fraile-Ribot","year":"2018","unstructured":"Fraile-Ribot PA, Cabot G, Mulet X, Perianez L, Martin-Pena ML, Juan C, Perez JL, Oliver A (2018) Mechanisms leading to in vivo ceftolozane\/tazobactam resistance development during the treatment of infections caused by MDR Pseudomonas aeruginosa. J Antimicrob Chemother 73(3):658\u2013663","journal-title":"J Antimicrob Chemother"}],"container-title":["European Journal of Clinical Microbiology &amp; Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-021-04363-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10096-021-04363-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-021-04363-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T01:03:41Z","timestamp":1642640621000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10096-021-04363-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,16]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["4363"],"URL":"https:\/\/doi.org\/10.1007\/s10096-021-04363-7","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"value":"0934-9723","type":"print"},{"value":"1435-4373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,16]]},"assertion":[{"value":"27 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"JMI Laboratories contracted to perform services in 2018\u20132021 for Achaogen, Inc., Affinity Biosensors, Albany College of Pharmacy and Health Sciences, Allecra Therapeutics, Allergan, Amicrobe Advanced Biomaterials, Inc., American Proficiency Institute, AmpliPhi Biosciences Corp., Amplyx Pharma, Antabio, Arietis Corp., Arixa Pharmaceuticals, Inc., Artugen Therapeutics USA, Inc., Astellas Pharma Inc., Athelas, Becton, Basilea Pharmaceutica Ltd., Bayer AG, Becton, Beth Israel Deaconess Medical Center, BIDMC, bioMerieux, Inc., bioMerieux SA, BioVersys Ag, Boston Pharmaceuticals, Bugworks Research Inc., CEM-102 Pharmaceuticals, Cepheid, Cidara Therapeutics, Inc., Cipla, Contrafect, Cormedix Inc., Crestone, Inc., Curza, CXC7, DePuy Synthes, Destiny Pharma, Dickinson and Company, Discuva Ltd., Dr. Falk Pharma GmbH, Emery Pharma, Entasis Therapeutics, Eurofarma Laboratorios SA, Fedora Pharmaceutical, F. Hoffmann-La Roche Ltd., Fimbrion Therapeutics, US Food and Drug Administration, Fox Chase Chemical Diversity Center, Inc., Gateway Pharmaceutical LLC, GenePOC Inc., Geom Therapeutics, Inc., GlaxoSmithKline plc, Guardian Therapeutics, Hardy Diagnostics, Harvard University, Helperby, HiMedia Laboratories, ICON plc, Idorsia Pharmaceuticals Ltd., IHMA, Iterum Therapeutics plc, Janssen Research & Development, Johnson & Johnson, Kaleido Biosciences, KBP Biosciences, Laboratory Specialists, Inc., Luminex, Matrivax, Mayo Clinic, Medpace, Meiji Seika Pharma Co., Ltd., Melinta Therapeutics, Inc., Menarini, Merck & Co., Inc., Meridian Bioscience Inc., Micromyx, Microchem Laboratory, MicuRx Pharmaceutics, Inc., Mutabilis Co., N8 Medical, Nabriva Therapeutics plc, National Institutes of Health, NAEJA-RGM, National University of Singapore, North Bristol NHS Trust, Novartis AG, Novome Biotechnologies, Oxoid Ltd., Paratek Pharmaceuticals, Inc., Pfizer, Inc., Pharmaceutical Product Development, LLC, Polyphor Ltd., Prokaryotics Inc., QPEX Biopharma, Inc., Ra Pharmaceuticals, Inc., Rhode Island Hospital, RIHML, Roche, Roivant Sciences, Ltd., Safeguard Biosystems, Salvat, Scynexis, Inc., SeLux Diagnostics, Inc., Shionogi and Co., Ltd., SinSa Labs, Specific Diagnostics, Spero Therapeutics, Summit Pharmaceuticals International Corp., SuperTrans Medical LT, Synlogic, T2 Biosystems, Taisho Pharmaceutical Co., Ltd., TenNor Therapeutics Ltd., Tetraphase Pharmaceuticals, The Medicines Company, The University of Queensland, Theravance Biopharma, Thermo Fisher Scientific, Tufts Medical Center, Universite de Sherbrooke, University of Colorado, University of Southern California-San Diego, University of Iowa, University of Iowa Hospitals and Clinics, University of North Texas Health Science Center, University of Wisconsin, UNT System College of Pharmacy, URMC, UT Southwestern, VenatoRx, Viosera Therapeutics, Vyome Therapeutics Inc., Wayne State University, Wockhardt, Yukon Pharmaceuticals, Inc., Zai Lab, and Zavante Therapeutics, Inc. There are no speakers\u2019 bureaus or stock options to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author disclosure statement"}}]}}